Pharmaceuticals 'Cannabics' Study Shows Cannabinoids CBNA and CBCA Cause Similar Necrosis to Their Non-acid Form
One of the leaders in personalized cannabinoids based on cancer and its side effects, announced today that cannabinoids CBN (Cannabinol) and CBC (Cannabichromene) and their acid form were shown to have necrotic effects on human colon cancer cells in a preclinical study held at the High Throughput Screening (HTS) facilities of cannabics Pharmaceuticals Inc. in Israel.
Cannabinoids CBNA and CBCA cause living tissue to die in colon cancer
CBN is a mildly psychoactive cannabinoid found only in trace amounts in Cannabis. Degraded or oxidized cannabis oils have a high concentration of CBN. CBN is the degraded product of tetrahydrocannabinolic acid (THCA). THCA turns into cannabinolic acid (CBNA) when exposed to air or ultraviolet light for an extended period of time. CBN is then formed by decarboxylation of CBNA.
The results obtained in the laboratory are complementary to our previous results, indicating that some cannabinoids are more toxic to cancer cells in their carboxylated form and others in their acid form.
The company continues to screen libraries of cannabinoid compounds at the company's facilities in Israel, while seeking to create proprietary formulations targeting cancer.
Dr Ilan Hochman, vice president of R&D of the company: “Cannabinoids have various biological pathways which are revealed by numerous scientific studies. The current results add to the complexity of our observations justifying a solid preclinical science as a major step before clinical validation ”.
About Cannabics Pharmaceuticals
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) is a U.S. public company developing a platform that harnesses new drug screening tools and artificial intelligence to create cannabinoid-based therapies for cancer that are more accurate compared to patient profile. By developing tools to assess efficacy on a personalized basis, Cannabics is helping to advance cannabinoids into the future of cancer therapy. The company's R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer. For more information, please visit www.cannabics.com.